Comparative Pharmacology
Head-to-head clinical analysis: TIMOPTIC versus TIMOPTIC XE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMOPTIC versus TIMOPTIC XE.
TIMOPTIC vs TIMOPTIC-XE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors in the ciliary epithelium.
Timolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 adrenergic receptors. In the eye, it reduces aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium, thereby lowering intraocular pressure.
One drop of 0.25% or 0.5% solution in the affected eye(s) twice daily.
Instill one drop of 0.25% or 0.5% solution in the affected eye(s) once daily in the morning.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy adults; prolonged in renal impairment.
Plasma: 4-6 hours; prolonged in renal impairment. Systemic half-life after ocular dosing: 4-5 hours.
Renal elimination: ~20% unchanged; biliary/fecal elimination: ~80% as metabolites.
Renal: 20% unchanged; remainder as metabolites via urine. Minor biliary/fecal elimination.
Category C
Category C
Ophthalmic Beta Blocker
Ophthalmic Beta Blocker